- Date of the board of directors resolution: May 11, 2018
- Source of capital increase funds: ash-increase of common shares to issue overseas depository receipts
- Number of shares issued: no more than 15,000,000 shares
- Par value per share: NT$10
- Total monetary amount of the issue: To be determined
- Issue price: To be determined
- Number of shares subscribed by or allotted to employees: To be determined
- Number of shares publicly sold: To be determined
- Ratio of shares subscribed by or allotted as stock dividends to existing shareholders: To be determined
- Method of handling fractional shares and shares unsubscribed by the deadline: To be determined
- Rights and obligations of the newly issued shares: same as existing common shares
- Utilization of the funds from the capital increase: enrich working capital to support new drug research and development
- Any other matters that need to be specified: the case will be raised in the 2018 Annual General Meeting